CymaBay meets pri­ma­ry, key sec­ondary end­points in PhI­II liv­er tri­al

CymaBay Ther­a­peu­tics’ lead can­di­date met the pri­ma­ry end­point and key sec­ondary end­points in a Phase III tri­al for a liv­er dis­ease, set­ting the stage for the biotech to pur­sue ap­proval of a drug that failed to ad­vance as a treat­ment for NASH.

The com­pa­ny on Thurs­day re­vealed the re­sults from the RE­SPONSE tri­al, which looked at se­ladel­par in pri­ma­ry bil­iary cholan­gi­tis (PBC), an au­toim­mune dis­ease in the liv­er that even­tu­al­ly de­stroys the body’s bile ducts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER